Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders elected four Class III directors, including CEO Nello Mainolfi, to three-year terms ending in 2029.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders elected four Class III directors, including CEO Nello Mainolfi, to three-year terms ending in 2029
- Executive compensation approved on an advisory basis, with 74,903,687 votes for and 2,462,732 against
- Ernst & Young LLP ratified as independent auditor for fiscal year 2026, with 79,043,801 votes for
- Director elections and compensation approval indicate continued shareholder support for Kymera’s leadership and governance slate
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.